Optimization for Regorafenib in HCC (ReDos HCC)
A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib
Sponsor: Bayer
Terminated
Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.
Other terminated trials from Bayer
Other Hepatocellular Carcinoma trials with similar outcome
Listed as NCT04476329, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Nov 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- SC Liver Research Consortium, LLC
For direct contact, visit the study record on ClinicalTrials.gov .